AT290542B - Verfahren zur Herstellung von neuen Chinazolinderivaten - Google Patents

Verfahren zur Herstellung von neuen Chinazolinderivaten

Info

Publication number
AT290542B
AT290542B AT1088169A AT1088169A AT290542B AT 290542 B AT290542 B AT 290542B AT 1088169 A AT1088169 A AT 1088169A AT 1088169 A AT1088169 A AT 1088169A AT 290542 B AT290542 B AT 290542B
Authority
AT
Austria
Prior art keywords
production
quinazoline derivatives
new quinazoline
new
derivatives
Prior art date
Application number
AT1088169A
Other languages
German (de)
English (en)
Inventor
Luigi Bernardi
Alberto Bonsignori
Severina Coda
Giselbert Karl Suchowsky
Original Assignee
Farmaceutici Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutici Italia filed Critical Farmaceutici Italia
Application granted granted Critical
Publication of AT290542B publication Critical patent/AT290542B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT1088169A 1968-11-26 1969-11-21 Verfahren zur Herstellung von neuen Chinazolinderivaten AT290542B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2416068 1968-11-26

Publications (1)

Publication Number Publication Date
AT290542B true AT290542B (de) 1971-06-11

Family

ID=11212294

Family Applications (1)

Application Number Title Priority Date Filing Date
AT1088169A AT290542B (de) 1968-11-26 1969-11-21 Verfahren zur Herstellung von neuen Chinazolinderivaten

Country Status (16)

Country Link
US (1) US3660322A (US20110009641A1-20110113-C00116.png)
AT (1) AT290542B (US20110009641A1-20110113-C00116.png)
BE (1) BE742205A (US20110009641A1-20110113-C00116.png)
BR (1) BR6914433D0 (US20110009641A1-20110113-C00116.png)
CH (1) CH523892A (US20110009641A1-20110113-C00116.png)
DE (1) DE1958515B2 (US20110009641A1-20110113-C00116.png)
DK (1) DK123239B (US20110009641A1-20110113-C00116.png)
ES (1) ES373909A1 (US20110009641A1-20110113-C00116.png)
FR (1) FR2024241B1 (US20110009641A1-20110113-C00116.png)
GB (1) GB1231959A (US20110009641A1-20110113-C00116.png)
IE (1) IE33406B1 (US20110009641A1-20110113-C00116.png)
IL (1) IL33393A (US20110009641A1-20110113-C00116.png)
NL (1) NL147140B (US20110009641A1-20110113-C00116.png)
NO (1) NO123430B (US20110009641A1-20110113-C00116.png)
SE (1) SE360659B (US20110009641A1-20110113-C00116.png)
YU (1) YU33286B (US20110009641A1-20110113-C00116.png)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
DE3815767A1 (de) * 1988-05-09 1989-11-23 Karl Niggemeier Abhefter fuer einzelblaetter
KR950701322A (ko) * 1992-05-07 1995-03-23 조셉 에프. 디프리마 사람면역결핍바이러스 역전사효소의 억제제로서의 신규한 퀴나졸린(New quinazolines as inhibitors of HIV reversetranscriptase)
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
CA2322203A1 (en) * 1998-03-27 1999-10-07 Jeffrey W. Corbett 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
IE33406L (en) 1970-05-26
SE360659B (US20110009641A1-20110113-C00116.png) 1973-10-01
DK123239B (da) 1972-05-29
FR2024241A1 (US20110009641A1-20110113-C00116.png) 1970-08-28
IL33393A (en) 1973-04-30
NL147140B (nl) 1975-09-15
FR2024241B1 (US20110009641A1-20110113-C00116.png) 1973-07-13
ES373909A1 (es) 1972-08-16
YU292269A (en) 1976-03-31
IL33393A0 (en) 1970-01-29
US3660322A (en) 1972-05-02
GB1231959A (US20110009641A1-20110113-C00116.png) 1971-05-12
CH523892A (de) 1972-06-15
DE1958515B2 (de) 1976-06-24
DE1958515A1 (de) 1970-07-09
BE742205A (US20110009641A1-20110113-C00116.png) 1970-05-25
IE33406B1 (en) 1974-06-12
NL6917085A (US20110009641A1-20110113-C00116.png) 1970-05-28
YU33286B (en) 1976-08-31
NO123430B (US20110009641A1-20110113-C00116.png) 1971-11-15
BR6914433D0 (pt) 1973-02-22

Similar Documents

Publication Publication Date Title
AT301020B (de) Verfahren zur Herstellung von neuen α-Amino-cyclohexadienylalkylen-penicillinen und -cephalosporinen
AT301544B (de) Verfahren zur Herstellung von neuen Chromonen
CH513152A (de) Verfahren zur Herstellung von neuen Dibenz-oxepinen, -thiepinen und -azepinen
AT308981B (de) Verfahren zur Herstellung von neuen Perhydrobenzindenen
CH517819A (de) Verfahren zur Herstellung von neuen Farbstoffen
AT287198B (de) Verfahren zur Herstellung von neuen Penicillinen
CH558342A (de) Verfahren zur herstellung von neuen phenolderivaten.
CH501650A (de) Verfahren zur Herstellung von neuen Azepinderivaten
AT290542B (de) Verfahren zur Herstellung von neuen Chinazolinderivaten
AT293640B (de) Verfahren zur Herstellung von neuen Oxydo-cardadienoliden und -bufatrienoliden
AT293425B (de) Verfahren zur Herstellung von neuen Bisammoniumverbindungen
CH525893A (de) Verfahren zur Herstellung von neuen Benzomorphanderivaten
AT284834B (de) Verfahren zur Herstellung von neuen Triazolyl-cumarinen
CH524630A (de) Verfahren zur Herstellung von neuen 2-Desoxyuridinen
AT276421B (de) Verfahren zur Herstellung von neuen 4-Alkoxy-propylenharnstoff-bzw. -thioharnstoffderivaten
AT290522B (de) Verfahren zur Herstellung von neuen Cumarinderivaten
AT289296B (de) Verfahren zur Herstellung von neuen Penicillinen
AT309703B (de) Verfahren zur Herstellung von neuen 9α-unsubstituierten 11β-Chlor-19-norsteroiden
CH523256A (de) Verfahren zur Herstellung von neuen Bisimidazolyl-bisphenylmethanen
AT281863B (de) Verfahren zur Herstellung von neuen Hydantoinderivaten
AT296498B (de) Verfahren zur Herstellung von neuen Penicillinen
AT311981B (de) Verfahren zur Herstellung von neuen Chinazolinderivaten
AT291280B (de) Verfahren zur Herstellung von neuen Harnstoffderivaten
AT291278B (de) Verfahren zur Herstellung von neuen Harnstoffderivaten
AT290029B (de) Verfahren zur Herstellung von neuen 2-Halogen-18-methyl-1-androstenen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee